Latest Breaking News On - Mathilde bohin - Page 16 : comparemela.com

Implanet s Annual General Meeting on the Second Call Will Be Held on June 9, 2022 at 2 pm CEST

Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral implants, informs its shareholders

United statesFrance generalArthur rouillF magendie technopole bordeauxMathilde bohinNicolas fossiezDavid dieumegardLudovic lastennetOrthopaedic spine developmentCompany onDrug administrationRegulatory newsEuronext growthAnnual general meetingTechnopole bordeaux montesquieuThursday june

GeNeuro: Availability of Documents and Information for the Annual Shareholders Meeting of May 31, 2022

Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO) (Paris:GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis

France generalPlan les ouatesArthur rouillMathilde bohinLouis victor delouvrierFeuille officielle suisseRegulatory newsEuronext parisGeneral meetingTuesday mayOrdinary general meetingInvestors documentation shareholders

GeNeuro Publishes Its 2021 Universal Registration Document

GeNeuro Publishes Its 2021 Universal Registration Document
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalArthur rouillLouis victor delouvrier mathilde bohinEuronext parisRegistration documentDes marchAnnual shareholder meetingVictor delouvrierMathilde bohin

IMPLANET Reports Q1 2022 Revenue

Q1 2022 revenue doubles to €2.02 million (vs. Q1 2021), driven by the organic growth of its JAZZ activity and the strategic acquisition of OSD Acceleration in activity in France (x2.7) and

United statesFrance generalMathilde bohinNicolas fossiezNicolas merigeauDavid dieumegardLudovic lastennetOrthopaedic spine developmentDrug administrationEuronext growthGeneral meeting

Oncodesign Confirms Its Very Good Results in 2021 and an Attractive Outlook For 2022

Group turnover up by 23% at €31.3 millionOperating income and revenue of €36.2M, offsetting the foreseen discontinuation of the GSK subsidy (€8M)R&D investments amounting to €7.4MNet profit/loss near the break-even point (-€0.3M)Service BU:Very strong organic growth in external turnover at +31%, reaching €27.6M,EBIT.

United statesFrance generalArnaud lafforgueMathilde bohinLes ulisPhilippe genneUniversity hospitalInvestments in researchResearch tax creditOncodesign groupBusiness developmentRegulatory newsBusiness unitsArtificial intelligenceChief financial officerNorth american